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Major capsid protein L1 of HPV16 was produced in a fused form in Escherichia coli using an inducible expression system.
The protein formed insoluble aggregations (inclusion bodies) and the yield was more than 10% of total cell proteins. The
inclusion bodies were isolated and solubilised with 8 M urea and the L1 proteins were purified by chromatographic
separation. Following removal of the urea by gradual dialysis, the denatured L1 proteins spontaneously renatured and
subsequently assembled into polymorphologic aggregations in vitro. Electron microscopy showed that the assembled
material included structures resembling native empty capsids as well as incompletely formed capsids. After separation from
the pool of polymorphologic structures by sucrose gradient sedimentation, the correctly formed virus-like particles (VLE.
coliPs) were recognised by a HPV16 type-specific, conformational-dependent monoclonal antibody in an ELISA. This system
offers not only a model for investigation of the intrinsic interactions that occur during L1 assembly, but also a potential route
for convenient manufacture of highly purified VLP vaccines. © 1998 Academic Press
INTRODUCTION
Papillomaviruses are nonenveloped, double-stranded
DNA viruses that infect a range of mammalian species
(zur Hausen, 1994; Galloway and McDougall, 1989). Of
the 70 types that infect humans, papillomavirus type 16
(HPV16) is associated with the development of high-
grade cervical intraepithelial neoplasia (CIN), which, if
untreated, is likely to progress to cancer of the cervix
(Bosch et al., 1995). HPV16 is thus described as a ‘‘high-
risk’’ papillomavirus.
The inability to propagate papillomaviruses in vitro has
hampered both the development of an attenuated virus
vaccine and detailed molecular investigation of virus
assembly. To this end, heterogeneic eukaryotic expres-
sion systems have been employed to generate empty
viral capsids (virus-like particles (VLPs)) which sponta-
neously assemble from preparations of correctly folded
recombinant capsid proteins. The major capsid protein,
L1, which has a relative molecular weight of 55 kDa by
reducing SDS–PAGE (Doorbar and Gallimore, 1987), will
assemble into VLPs (Hagensee et al., 1993; Kirnbauer et
al., 1992, 1993; Rose et al., 1993; Sasagawa et al., 1995;
Heino et al., 1995). Coexpression of L1 with the minor
capsid protein, L2, which has a relative molecular weight
of 72 kDa by reducing SDS–PAGE (Doorbar and Galli-
more, 1987), results in the incorporation of L2 into VLPs
(Kirnbauer et al., 1993; Hagensee et al., 1993), although
the exact localisation of L2 into the VLP is not clear. The
three-dimensional image of the assembled capsid is a
T 5 7 icosahedral lattice, 55 nm in diameter, which is
assembled from 72 pentamers of L1 (Baker et al., 1991).
VLPs have not only provided a convenient model sys-
tem for investigation of the structural properties of the
capsid (Sapp et al., 1995) and the interactions of the
capsid with the cell surface (Mu¨ller et al., 1995; Roden et
al., 1995; Volpers et al., 1995), but they are also attractive
candidates for a prophylactic vaccine against papilloma-
virus infection. The latter is supported by the demonstra-
tion that VLPs are highly immunogenic, eliciting an im-
mune response that is very similar to the response elic-
ited by native virions (Kirnbauer et al., 1992; Breitburd et
al., 1995; Roden et al., 1994). Furthermore, complete
protection against canine oral papillomavirus (COPV)
challenge was demonstrated in dogs, previously vacci-
nated with 20-mg doses of COPV VLPs. This protection is
likely to be mediated by the strong antibody response,
generated by VLP vaccination (Suzich et al., 1995).
Although VLPs generated in eukaryotic systems stim-
ulate a strong immune response to native papillomavirus
epitopes, thus eliciting neutralising antibodies in the
host, production of VLPs in a prokaryotic system remains
an attractive option for reasons of yield, ease of purifi-
cation, and cost. A number of studies have reported
successful expression of HPV L1 proteins in bacteria
(Banks et al., 1987; Doobar and Gallimore, 1987; Li et al.,
1987; Thompson and Roman, 1987; Jenison et al., 1988)
but until recently, it appeared that such system could
only generate incorrectly folded protein with consider-
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ably less immunogenicity than properly assembled par-
ticles. In this report, we describe the expression of
HPV16 L1 in the form of insoluble inclusion bodies (IBs)
and the subsequent renaturation and self-assembly of
this protein into virus-like particles (termed VLE. coliPs)
that not only morphologically resemble those particles
(termed VLBacPs) derived via expression by baculovirus
recombinants, but are also recognised by HPV16 confor-
mational-dependent antibody. This system could offer
practical advantages over those in which VLPs are pro-
duced directly within the host, in that more rigorous
purification methods could be used to generate material
free of contamination.
RESULTS
Expression and characterisation of HPV16 L1
expressed in E. coli
The induction of HPV16 L1 expression in IPTG-treated
cultures of pET16L1-transformed E. coli HMS174 (DE3)
(Fig. 1) was analysed by reducing SDS–PAGE. As shown
in Fig. 2A, a protein of approximately 60 kDa mass
accumulated in cell lysates of IPTG-treated cultures (Fig.
2A, lane 2). This protein was not detected in uninduced
cultures (Fig. 2A, lane 1). The identity of the 60-kDa
protein as L1 was confirmed by Western blotting using
the anti-L1 monoclonal antibody Camvir 1. The antibody
reacted strongly to the 60-kDa protein, as well as to
some lower molecular weight proteins (Fig. 2B, lane 2)
which may result from the degradation of the full-length
L1 or premature termination of translation. Cell lysates
from uninduced cultures were not recognised by this
antibody (Fig. 2B, lane 1).
The observed molecular weight is approximately 5
kDa greater than previously determined, due to the fu-
sion of the coding sequence at the amino terminus to 31
amino acids including a 24-amino-acid leader sequence,
pelB, and at the carboxyl terminus to six histidine resi-
dues (His tag). To confirm that the L1 was indeed fused
to these sequences, the 60-kDa protein was subjected to
N-terminal amino acid analysis. The result showed that
the first 5 amino acids of the protein are Met-Lys-Tyr-
Leu-Leu, which is identical to the N-terminal sequence of
pelB leader encoded by the expression vector pET-22b
(Novagen). In addition, Western blotting (Fig. 3) con-
firmed that the 60-kDa L1 protein is tagged by multiple
histidine residues. The anti His-tag monoclonal antibody,
RGSHis (QIAGEN), recognised the 60-kDa L1 protein in
the lysate of IPTG-induced E. coli cells (Fig. 3, lane 2), but
did not recognise the 60-kDa proteins in the lysate of
uninduced E. coli cells (Fig. 3, lane 1) or the full-length L1
proteins from denatured VLBacPs (Fig. 3, lane 3).
The yield of this 60-kDa fusion L1 protein expressed in
E. coli cells after IPTG induction was estimated by den-
sitometric scanning following SDS–PAGE and Coomas-
sie blue staining of cell total extracts. L1 was determined
as comprising 10–15% of the total cellular protein. The
overexpressed L1 was accumulated in the cells as IBs
which could be visualised by electron microscopy (data
not shown). IBs were isolated as described under Mate-
rials and Methods and the insoluble pellet divided into
four and treated with 8.0, 6.0, 4.0, and 2.0 M urea, re-
spectively. As shown in Fig. 4, none of the supernatants
generated during the isolation of IBs contained the ex-
pressed protein (Fig. 4, lanes 1–3), whereas L1 was
FIG. 2. Analysis of the expression of HPV16 L1 in E. coli HMS174
(DE3) cells from the recombinant expression vector pET16L1 by (A)
SDS–PAGE and (B) Western blotting. The samples analysed are the
lysates of uninduced (lane 1) and induced (lane 2) cells. Lane M,
molecular weight markers. The anti-HPV16 L1 monoclonal antibody
Camvir 1 was used in Western blotting.
FIG. 1. Construction of HPV16 L1 expression vector pET16L1. The L1 coding sequence was amplified by PCR from the W12 cell line and cloned
into BamHI and NotI sites of the a pET22b-based E. coli expression vector pGW046.
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effectively solubilised in the 8.0 M urea (Fig. 4, lane 4),
partially solubilised in 6.0 and 4.0 M urea (Fig. 4, lanes 5
and 6), and insoluble in 2.0 M urea (Fig. 4, lane 7). This
indicated that L1, expressed in E. coli as IBs, is highly
insoluble.
Purification of the insoluble L1 protein
The accumulation of prokaryotically expressed L1 in
IBs facilitated its purification as the IBs could be isolated
by the series of centrifugation and wash steps outlined
under Materials and Methods. This resulted in a prepa-
ration that was observed by reducing SDS–PAGE as
being partially pure (Fig. 5, lane 1). Subsequent cation
exchange chromatography using CM–Sepharose fast
flow, in the presence of 8 M urea under weakly acidic
conditions (pH 6.8), resulted in further purification of L1.
No L1 was eluted during the application of the L1 or
during the wash step, which used 100 mM NaCl to
remove weakly bound host cell proteins (Fig. 5, lanes
2–3). L1 was eluted from the column with 500 mM NaCl
(Fig. 5, lane 4).
In vitro self-assembly of purified L1 protein
The conditions applied to solubilise and purify L1 re-
sulted in the protein being denatured and reduced. In order
to promote the refolding of purified L1 to its native confor-
mation and the subsequent self-assembly of L1 into VLPs,
the denaturant was completely removed by a stepwise
dialysis procedure as described under Materials and Meth-
ods. Examination of the final preparation of renatured L1 by
electron microscopy under negative staining (Fig. 6) dem-
onstrated that L1 assembled into incomplete and complete
VLPs during the dialysis procedure. The completely assem-
bled VLE. coliPs were 50–60 nm in diameter and morpho-
logically indistinguishable from VLBacPs (Fig. 6, insert).
Examination of the VLE. coliPs after 2 months storage at
4°C in buffer A demonstrated that the particles are confor-
mationally stable.
To analyse the efficiency with which the renatured L1
self-assembles in vitro into VLE. coliPs via the dialysis
process, a 10–55% sucrose gradient sedimentation was
used to separate VLE. coliPs from polymorphological
structures in the dialysed preparation as described un-
der Materials and Methods. Fractions were analysed by
Western blotting with anti-L1 monoclonal antibody Cam-
vir 1. A small percentage of the L1 protein banded at the
higher density region, while most of the proteins re-
mained at top of the gradient (data not shown), suggest-
ing that the L1 protein was present predominantly in an
unassembled state in the dialysed preparation. Further,
the HPV16 conformational-dependent monoclonal anti-
body H16 V5 was used in an ELISA as a direct test of the
fractions which contained completely formed VLE. coliPs
(Fig. 7A). It was found that only the samples from the
bottom part of the gradient (fractions 21–25) showed a
FIG. 3. Detection of His tag residues in the L1 protein, which was
expressed by IPTG-induced pET16L1-transformed HMS174 cells. The
total cell extracts from uninduced cells (lane 1) or IPTG-induced cells
(lane 2) or L1 protein denatured from VLBacPs (lane 3) were subjected
to two parallel SDS–PAGE, of which one was stained with 0.1% Coo-
massie blue (A) and the other was transferred onto a membrane for
Western blotting (B). The anti-His tag monoclonal antibody GSRHis was
used in the Western blotting.
FIG. 4. SDS–PAGE analysis of the protein contents in supernatant
fractions obtained during the isolation of IBs from induced cultures of
pET16L1-transformed E. coli HMS174 (DE3). The cell pellet was treated
with lysozyme (lane 1) and the insoluble material collected by centrif-
ugation and washed first with buffer A containing 10 mM MgCl2 (lane
2) and then by buffer A containing 1% (v/v) Triton X-100 (lane 3). The
washed pellet was divided into four parts and solubilised with buffer A
containing 8 M (lane 4), 6 M (lane 5), 4 M (lane 6), and 2 M (lane 7) urea,
respectively. Molecular weight markers are shown in lane M.
FIG. 5. SDS–PAGE analysis of HPV16 L1 in the fractions collected
after ion-exchange chromatography. The IBs, solubilised in 8 M urea
(lane 1), were applied to a CM–Sepharose column equilibrated at pH
6.8 and the unbound material was collected (lane 2). Following the
removal of weakly bound proteins (lane 3) by a low-salt wash (100 mM
NaCl), L1 was eluted from the column with buffer containing 500 mM
NaCl (lane 4). The protein molecular weight markers were loaded
adjacently (lane M).
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detectable signal. This observation suggests that cor-
rectly formed particles were present in these fractions.
To quantify the VLE. coliPs which were isolated by the
sedimentary centrifugation, fractions 21–25 from each of
the sucrose gradients were diluted, centrifuged, and
used to react with antibody H16 V5 in an ELISA. In the
same assay, VLBacPs were used in different amounts as
quantitive controls (Fig. 7B). It was found that the wells
coated with collected materials of fractions 21–25 had
developed an optical density (OD450 nm) value of 0.30–
0.55, which was relevant to the OD450 nm value of about
20–50 ng of VLBacPs to H16 V5. As approximately 0.1 mg
of dialysed L1 protein was initially subjected to each of
the sucrose gradients, 20–50 ng was determined to be
assembled into VLE. coliPs, thus giving an efficiency of
0.02–0.05%. The fact that these VLE. coliPs reacted with
H16 V5, a well-characterised conformational-dependent
HPV16-specific neutralising antibody, demonstrates that
a type-specific conformational epitope is located on
these structures.
DISCUSSION
This report has described the in vitro assembly of
HPV16 VLE. coliPs following the solubilisation of bacte-
rially expressed HPV16 L1 in 8 M urea and subsequent
purification and renaturation. Electron microscopy of the
negatively stained renatured preparation confirmed the
FIG. 6. Electron micrograph of E. coli-expressed HPV16 L1 proteins that have been renatured and have self-assembled into VLE. coliPs in vitro.
The completely assembled VLE. coliPs are morphologically similar to the HPV16 VLBacPs purified from insect cells after infection with recombinant
baculovirus (inserted micrograph). The samples were negatively stained.
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presence of VLPs with a relatively uniform size of 50–60
nm in diameter. This observation indicates that the in
vitro assembled VLPs resemble, in morphology, VLBacPs
assembled in eukaryotic baculovirus systems. Further,
we also show that these in vitro assembled particles
display a conformational/neutralisisng epitope(s).
The assembly in vitro of bacterially expressed viral
structural proteins into VLPs has been demonstrated in
several previous studies, including polyoma VP1 (Sal-
unke et al., 1986), hepatitis B core antigen (Stahl et al.,
1982), and very recently the HPV11 L1 protein (Li et al.,
1997). In these studies, the viral structural proteins ex-
pressed in bacterial cells were soluble and associated
into pentameric capsomers or capsid-like particles
within the bacterial compartment. However, this was not
the case with the bacterially expressed HPV16 L1 in this
study. Examination of IPTG-induced cells by thin-section
electron microscopy did not reveal any VLP structures or
any lattice arrangements which would imply the pres-
ence of capsomeric assemblies (data not shown). In fact,
the L1 proteins accumulated in the cell as insoluble
aggregates, IBs, which could only be solubilised with
high concentrations of denaturant. Therefore, a denatur-
ation–renaturation process was employed to restore the
native folding of the protein and thus to promote the
assembly of L1 into VLE. coliPs.
In this study, VLE. coliPs self-assembled in vitro from a
fusion protein of L1. Fusion of the L1 N-terminus to the
pelB leader sequence was thought to enhance the sta-
bility of the foreign protein with regard to enzymatic
degradation and to effect secretion of the protein into the
periplasmic space. However, in this case, L1 accumu-
lated within the cytoplasm as IBs. The fusion of the
C-terminus to the positively charged His tag residue was
undertaken to allow the purification of L1 with ion-ex-
change chromatography. In addition to the fused L1 pro-
tein described above, we have also prepared unfused L1
protein from the same bacterial expression system and
analysed this for the capacity of self-assembly in vitro.
Briefly, a similar profile was observed to that of pET16L1-
expressed fusion L1 protein; thus the protein was ex-
pressed at a high level but accumulated as IBs. It is
unclear whether the unfused L1 protein could be self-
assembled into a better yield of VLE. coliPs under the
denaturation–renaturation process, as it was very diffi-
cult to purify this neutral-charged protein from bacterial
contamination.
After a range of conditions were examined for effective
renaturation of L1 protein in vitro, a number of factors
were identified that affect L1 renaturation and VLP as-
sembly. First, the purity of the L1 protein was crucial, as
bacterial contaminants interfere with renaturation. To
this end, an ion-exchange chromatography step was
employed prior to the renaturation process. Second, the
concentration of L1 during the renaturation was also
important, as misfolding and intermolecular aggregation
occur at high protein concentrations; thus, the renatur-
ation was performed at a protein concentration of about
0.1 mg/ml. Third, the rate at which the denaturant and
reducing agent is removed from the preparation was
also important in encouraging folding to the native con-
formation. In this study, it was found that a gradual
reduction in urea and DTT concentrations by four dialysis
steps could minimise L1 aggregation during renatur-
ation. In addition, renaturation was dependent on pH and
ionic strength. The selected conditions for the renatur-
ation and assembly of L1 in this study were at pH 8.0 and
under a low-salt concentration (100 mM NaCl).
Although the above conditions are essential for in vitro
assembly of L1 into VLE. coliPs consistently, the yield of
correctly formed VLE. coliPs was low. A possible expla-
nation may be the inefficient reformation of the correct
disulfate linkages following denaturation and renatur-
ation. It has been known that there are 12 cysteine
FIG. 7. A 10–55% sucrose sedimentation of VLE. coliPs. The gradient
was fractioned and VLE. coliPs were detected using the conformation-
al-specific monoclonal antibody H16 V5 in an ELISA (A). Fractions
21–25 were collected, diluted, and centrifuged to pellet VLE. coliPs.
Particles in each of the pellets (p1–p3) were tested with H16 V5 in an
ELISA (B), together with a range of concentration of VLBacPs as a
quantitive control.
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residues in the L1 amino acid sequence and L1 is prob-
ably a highly disulfide-bonded protein. As the rate and
yield of correct disulfide bond formation by air oxidation
generally are low (Ahmed et al., 1975), refolding of de-
natured L1 protein by a conventional dialysis procedure
over a 1- to 2-day period may not be sufficient time for the
molecule to achieve a stable native conformation. In this
case, the yield of VLE. coliPs could possibly be improved
by enhancing disulfate bond formation. Several methods
that enhance this during protein renaturation have been
described (Wetlaufer et al., 1987; DiBella et al., 1995) and
the work is in progress to improve the yield of HPV16
VLE. coliPs based on these studies.
The amino acid residues or domains of HPV16 L1
essential for capsid assembly have not been fully eluci-
dated. It has been shown previously that the aspartic
acid residue at position 202 is necessary for VLP forma-
tion by HPV16 L1 expressed via a baculovirus recombi-
nant (Kirnbauer et al., 1993). The HPV16 L1 DNA used in
the present study was derived from the HPV16 episomes
present in W12, a cell line established from a CIN I
lesion. Sequencing of this full-length L1 DNA identified
three nucleotide changes compared to the original pro-
totype (Seedorf et al., 1985). Two of these nucleotide
changes are the amino acid codons histidine to aspartic
acid at position 202 and threonine to alanine at position
266. These nucleotide changes have been observed
before in HPV16 genomes derived from low-grade clini-
cal biopsies (Kirnbauer et al., 1993; Pushko et al., 1994).
The third nucleotide substitution, nt 5962 T to C, does not
result in a change in amino acid. These data suggest that
the L1 ORF in the HPV16 in W12 cells encodes the
wild-type L1 protein. This is supported by the ability of
W12 cells to support permissive viral replication (Sterling
et al., 1990) and by the high efficiency with which bacu-
lovirus-expressed W12 HPV16 L1 protein assembles VL-
BacPs (data not shown).
The pET16L1 construct expresses L1 as a fusion pro-
tein with the coding sequence fused at the amino and
carboxyl termini to sequences encoded by the expres-
sion vector. However, we show in this report that this
protein can self-assemble, generating VLE. coliPs which
display conformational type-specific epitopes. Potentially
these structures are highly immunogenic and could be
useful in the development of safe readily purified HPV16
vaccine.
MATERIALS AND METHODS
1. Construction of the prokaryotic expression vector
pET16 L1
The L1 coding region, exclusive of the translation start
codon ATG (second) and stop codon TAA, was amplified
by the polymerase chain reaction (PCR) from the kerati-
nocyte cell line W12 (Stanley et al., 1989), in which mul-
tiple copies of the entire HPV16 genome are maintained
episomally. To maximise full-length protein expression
by avoidance of transcription termination (Earl et al.,
1990; Zhou et al., 1991), the amplification method of
overlap extension was used to effect mutagenesis of a
region of seven thymidylate bases at positions 6377–
6383 (inclusive) to TTCTTCT, thus maintaining the amino
acid coding sequence. In addition, a region of six ade-
nylate bases at positions 7139–7144 (inclusive) was
changed to AAGAAG, again conserving the amino acid
sequence, by including these base changes in the re-
verse amplification primer. Thus, a 753-base-pair (bp)
fragment encompassing the 59 half of the L1 coding
sequence was amplified using the following pair of prim-
ers, the forward primer incorporating a BglII restriction
site (underlined). Forward primer: 59 GATCAGATCT-
GTCTCTTTTGGCTGCCTAGTGAGGCC 39; reverse primer:
59 CGTAAATAGAAGAATAAGCTGTCG 39. A 798-bp frag-
ment encompassing the 39 half of the L1 coding region
was amplified using the following pairs of primers, the
reverse primer incorporating a NotI restriction site (un-
derlined). Forward primer: 59 CGACAGCTTATTCTTC-
TATTTACG 39; reverse primer: 59 CTAGCGGCCGC-
CAGCTTACGCTTCTTGCGTTTAGC 39. The two amplifica-
tion products were purified and used as a target for a
final amplification reaction using the flanking forward
and reverse primers incorporating a BglII and a NotI site,
respectively. The full-length, mutagenised L1 coding se-
quence thus amplified was cloned into a pGEM-T PCR
cloning vector (Promega) from which it was excised and
ligated into the bacterial expression vector pGW046, a
derivative of pET-22b (Novagen) that confers kanamycin
resistance, which had been digested with BamHI and
NotI. This created the L1 expression vector pET16L1 (Fig.
1). As indicated earlier, L1 coding sequence in the vector
did not include the translational start and stop codons;
thus, protein expression is initated from the start codon
of the vector-encoded pel B leader sequence and termi-
nated after the 39 His tag, thereby resulting in a fused L1
protein. The clone was confirmed by DNA sequencing
using the T7 sequencing kit (Pharmacia).
2. Expression of HPV16 L1 protein and immunoblot
detection
Escherichia coli HMS174 (DE3) cells (Novagen), trans-
formed with pET16L1, were cultured in the soya-based
medium 2YS (17.8 g/liter vegetable peptone, 11.1 g/liter
yeast extract, 5.6 g/liter NaCl) until the absorbance of the
culture at 600 nm against uninoculated medium was
1.0–1.2 units. L1 expression was then induced by the
addition of isopropyl-b-D-thiogalactopyranoside (IPTG) to
a concentration of 0.4 mM. After a 2-h induction period,
the cells were harvested by centrifugation at 5000 g for
15 min at 4°C.
L1 expression was monitored by reducing SDS–PAGE
of total cell lysates containing 20–30 mg protein and
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staining with Coomassie brilliant blue R (Sigma). For
further confirmation, cell lysates were electroblotted onto
Hybond-C membrane (Amersham Inc.) and the L1 pro-
tein was immunodetected using the anti-HPV16 L1
monoclonal antibody Camvir 1 (McLean et al., 1990) in
combination with the secondary antibody, peroxidase-
conjugated rabbit anti-mouse IgG (DAKO). The reaction
signals were detected using the chemiluminescent ECL
detection kit (Amersham Inc.).
3. Purification of L1 protein from inclusion bodies
A 500-ml induced culture of pET16L1-transformed E.
coli HMS174 was harvested by centrifugation as de-
scribed previously and the cells were washed with phos-
phate-buffered saline (PBS), pelleted by centrifugation,
and stored at 270°C until required. Once thawed, the
cell pellet was resuspended in buffer A [50 mM Tris–Cl
(pH 8.0), 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.1 mM
phenylmethylsulfonyl fluoride (PMSF), 100 mM NaCl]
containing 20% (w/v) sucrose and 1 mg/ml lysozyme.
After the lysis reaction was incubated for 30 min on ice,
the insoluble material was collected by centrifugation at
12,000 g for 15 min at 4°C. The insoluble pellet was then
washed, first by buffer A containing 10 mM MgCl2, then
by buffer A containing 1% (v/v) Triton X-100, and finally by
buffer A containing 2 M urea. Between each wash the
insoluble material, which is predominantly L1 protein in
IBs, was pelleted by centrifugation at 12,000 g for 15 min
at 4°C. The isolated IBs were solubilised in buffer B (50
mM Tris–Cl, pH 8.0, 5 mM EDTA, 10 mM DTT, 8 M urea).
The solubilisation process was carried out at room tem-
perature for 1 h with gentle agitation. Any remaining
insoluble debris was removed by centrifugation at 15,000
g for 15 min.
The solubilised L1 protein was applied to a CM–
Sepharose fast-flow (Pharmacia) column, previously
equilibrated with buffer C (50 mM Tris–Cl, pH 6.8, 5 mM
EDTA, 10 mM DTT, 8 M urea). The column was then
washed with buffer C containing 100 mM NaCl to remove
unbound and weakly bound contaminants prior to elution
of L1 with buffer C containing 500 mM NaCl. Proteins in
each collected fraction were analysed by reducing SDS–
PAGE and Coomassie blue staining.
4. Renaturation of L1 protein and sedimentary
purification of VLE. coliPs
To renature the purified L1 proteins, the high concen-
trations of denaturant (8 M urea) and reducing reagent
(10 mM DTT) were removed by a stepwise dialysis pro-
cedure whereby four 6-h dialysis steps were performed
against buffer A containing 4.0, 2.0, 1.0, and 0 M urea. All
steps in the renaturation of L1 protein were performed at
4°C. Any aggregated material formed during the dialysis
was removed by centrifugation at 20,000 g for 20 min.
The clarified supernatant was stored at 4°C until re-
quired.
Further purification of correctly formed VLE. coliPs
was achieved by centrifugation in a 10–55% sucrose
gradient in buffer A. One milliliter of dialysed protein
supernatant, at 0.1 mg/ml concentration, was loaded
onto the gradient (4 ml) and centrifuged at 4°C in a
SW55Ti rotor at 188,000 g for 2 h. The gradient was then
fractionated into 25 aliquots (approximately 200 ml each)
from the top of the centrifuge tube. The fractions were
then analysed by immunoblotting and enzyme-linked im-
munosorbent assay (ELISA), as described in Section 7.
5. Preparation of VLBacPs from baculovirus-
expressed L1
The L1 DNA of HPV16 was amplified by PCR from the
W12 cell line (described previously) using primers which
incorporate BglII restriction sites (underlined) as follows:
Forward primer: 59-GCTGCAAGATCTATGTCTCTTTG-
GCTGCCTAGT-39; reverse primer: 59-TCGAGCAGATCTT-
TACAGCTTACGTTTTTTGCG-39. The approximately 1.6-ki-
lobase (kb) amplification product was digested with BglII
and ligated into BamHI-digested pBacPAK1 (Clontech) to
give the recombinant pBac16L1. The L1 coding sequence
in pBac16L1 was confirmed by DNA sequencing using
the T7 sequencing kit (Pharmacia). pBac16L1 and AcM-
NPV DNA (BacPAK6; Clontech) were then used to co-
transfect into insect Sf21 cells and the recombinant
baculoviruses plaque purified (Summers and Smith,
1987) and further expanded by multiple cycles of cell
infection. The infection of Sf21 cells with the resulting
recombinant baculovirus and the purification of VLBacPs
from infected cells were performed as described previ-
ously (Kirnbauer et al., 1993).
6. Electron microscopy
The VLP preparation containing 100–300 mg/ml protein
was dropped in 5- to 10-ml quantities onto glow-dis-
charged carbon-coated grids and allowed to absorb for 2
min. Following of the removal of unabsorbed materials
from the grid, the material on each grid was stained with
2% (w/v) potassium phosphotungstic acid (pH 6.8) and
viewed with a Philip CM 100 transmission electron mi-
croscope.
7. ELISA
The identification and quantification of VLE. coliPs in
the sucrose fractions was achieved by ELISA testing with
the monoclonal antibody H16 V5 which recognises only
the native, nondenatured HPV16 VLPs (Christensen et
al., 1996). In brief, 20 ml of the sample was taken from
each of the 25 fractions and diluted 1:10 in PBS and used
to coat a 96-well ELISA plate (Nunc). As a negative
control, the wells were coated only with PBS, but the
same procedure was applied to the test samples. Ad-
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sorption of the applied protein to the plate was effected
by incubating at 4°C for 16 h. After the plate was washed
with PBS, the blocking buffer, i.e., 5% (w/v) dry milk in
PBS/0.1% Tween 20 (PBST), was applied to the wells and
the plate was incubated for 1 h at ambient temperature.
H16 V5 was diluted 1:50 in blocking buffer and applied to
the plates, which were then incubated at 37°C for 1 h.
After the plates were washed with PBST, the secondary
antibody, peroxidase-conjugated rabbit anti-mouse IgG
(DAKO), was used at a 1:2000 dilution. The unbound
antibody was removed by washing the plate with PBST
after incubating the plate for 1 h at 37°C. The bound
antibody was then stained using substrate, i.e., 4 mg of
o-phenylenediamine in 5 ml of 0.2 M Na2PO4 plus 0.1 M
citric acid with 2 ml 30% H2O2, and the signal was
developed at room temperature for 20 min under dark
conditions. The absorbance at 450 nm of each well was
then measured with a Dynatech MR5000 automated
plate reader.
In order to quantify the efficiency of the VLE. coliP
assembly, sucrose fractions which reacted positively
with the H16 V5 antibody in the ELISA were combined
and then diluted 1:5 with PBS for a further centrifugation
at 188,000 g for 2 h at 4°C. The pellet was gently resus-
pended in 100 ml of PBS and used to coat the ELISA
plate. As a quantity control, HPV16 VLBacPs at 5, 10, 50,
and 100 ng in 100 ml of PBS were coated onto the same
plate and ELISA was carried out as previously described.
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